Skip to main content

Publications

  1. Reitman ZJ, Paolella BR, Bergthold G, Pelton K, Becker S, Jones R, Sinai CE, Malkin H, Huang Y, Grimmet L, Herbert ZT, Sun Y, Weatherbee JL, Alberta JA, Daley JF, Rozenblatt-Rosen O, Condurat AL, Qian K, Khadka P, Segal RA, Haas-Kogan D, Filbin MG, Suva ML, Regev A, Stiles CD, Kieran MW, Goumnerova L, Ligon KL, Shalek AK, Bandopadhayay P, Beroukhim R. Mitogenic and progenitor gene programmes in single pilocytic astrocytoma cells. Nat Commun. 2019 Aug 19;10(1):3731. doi: 10.1038/s41467-019-11493-2. PubMed PMID: 31427603; PubMed Central PMCID: PMC6700116.
  2. Reitman ZJ, Winkler F, Elia AEH. New Directions in the Treatment of Glioblastoma. Semin Neurol. 2018 Feb;38(1):50-61. doi: 10.1055/s-0038-1623534. Epub 2018 Mar 16. Review. PubMed PMID: 29548052.
  3. Cagney DN, Martin AM, Catalano PJ, Reitman ZJ, Mezochow GA, Lee EQ, Wen PY, Weiss SE, Brown PD, Ahluwalia MS, Arvold ND, Tanguturi SK, Haas-Kogan DA, Alexander BM, Redig AJ, Aizer AA. Impact of pemetrexed on intracranial disease control and radiation necrosis in patients with brain metastases from non-small cell lung cancer receiving stereotactic radiation. Radiother Oncol. 2018 Mar;126(3):511-518. doi: 10.1016/j.radonc.2018.01.005. Epub 2018 Feb 3. PubMed PMID: 29398153.
  4. Chitneni SK, Reitman ZJ, Spicehandler R, Gooden DM, Yan H, Zalutsky MR. Synthesis and evaluation of radiolabeled AGI-5198 analogues as candidate radiotracers for imaging mutant IDH1 expression in tumors. Bioorg Med Chem Lett. 2018 Feb 15;28(4):694-699. doi: 10.1016/j.bmcl.2018.01.015. Epub 2018 Jan 12. PubMed PMID: 29366652; PubMed Central PMCID: PMC5817038.
  5. Song ZJ, Reitman ZJ, Ma ZY, Chen JH, Zhang QL, Shou XF, Huang CX, Wang YF, Li SQ, Mao Y, Zhou LF, Lian BF, Yan H, Shi YY, Zhao Y. The genome-wide mutational landscape of pituitary adenomas. Cell Res. 2016 Nov;26(11):1255-1259. doi: 10.1038/cr.2016.114. Epub 2016 Sep 27. PubMed PMID: 27670697; PubMed Central PMCID: PMC5099864.
  6. Chitneni SK, Reitman ZJ, Gooden DM, Yan H, Zalutsky MR. Radiolabeled inhibitors as probes for imaging mutant IDH1 expression in gliomas: Synthesis and preliminary evaluation of labeled butyl-phenyl sulfonamide analogs. Eur J Med Chem. 2016 Aug 25;119:218-30. doi: 10.1016/j.ejmech.2016.04.066. Epub 2016 Apr 28. PubMed PMID: 27163884; PubMed Central PMCID: PMC4893934.
  7. Reitman ZJ, Sinenko SA, Spana EP, Yan H. Genetic dissection of leukemia-associated IDH1 and IDH2 mutants and D-2-hydroxyglutarate in Drosophila. Blood. 2015 Jan 8;125(2):336-45. doi: 10.1182/blood-2014-05-577940. Epub 2014 Nov 14. PubMed PMID: 25398939; PubMed Central PMCID: PMC4287640.
  8. Reitman ZJ. Smaller protein, larger therapeutic potential: PPM1D as a new therapeutic target in brainstem glioma. Pharmacogenomics. 2014 Sep;15(13):1639-41. doi: 10.2217/pgs.14.123. PubMed PMID: 25410889.
  9. Reitman ZJ, Duncan CG, Poteet E, Winters A, Yan LJ, Gooden DM, Spasojevic I, Boros LG, Yang SH, Yan H. Cancer-associated isocitrate dehydrogenase 1 (IDH1) R132H mutation and d-2-hydroxyglutarate stimulate glutamine metabolism under hypoxia. J Biol Chem. 2014 Aug 22;289(34):23318-28. doi: 10.1074/jbc.M114.575183. Epub 2014 Jul 1. PubMed PMID: 24986863; PubMed Central PMCID: PMC4156049.
  10. Zhang L, Chen LH, Wan H, Yang R, Wang Z, Feng J, Yang S, Jones S, Wang S, Zhou W, Zhu H, Killela PJ, Zhang J, Wu Z, Li G, Hao S, Wang Y, Webb JB, Friedman HS, Friedman AH, McLendon RE, He Y, Reitman ZJ, Bigner DD, Yan H. Exome sequencing identifies somatic gain-of-function PPM1D mutations in brainstem gliomas. Nat Genet. 2014 Jul;46(7):726-30. doi: 10.1038/ng.2995. Epub 2014 Jun 1. PubMed PMID: 24880341; PubMed Central PMCID: PMC4073211.
  11. Killela PJ, Pirozzi CJ, Reitman ZJ, Jones S, Rasheed BA, Lipp E, Friedman H, Friedman AH, He Y, McLendon RE, Bigner DD, Yan H. The genetic landscape of anaplastic astrocytoma. Oncotarget. 2014 Mar 30;5(6):1452-7. doi: 10.18632/oncotarget.1505. PubMed PMID: 24140581; PubMed Central PMCID: PMC4039223.
  12. Killela PJ, Pirozzi CJ, Healy P, Reitman ZJ, Lipp E, Rasheed BA, Yang R, Diplas BH, Wang Z, Greer PK, Zhu H, Wang CY, Carpenter AB, Friedman H, Friedman AH, Keir ST, He J, He Y, McLendon RE, Herndon JE 2nd, Yan H, Bigner DD. Mutations in IDH1, IDH2, and in the TERT promoter define clinically distinct subgroups of adult malignant gliomas. Oncotarget. 2014 Mar 30;5(6):1515-25. doi: 10.18632/oncotarget.1765. PubMed PMID: 24722048; PubMed Central PMCID: PMC4039228.
  13. Reitman ZJ, Pirozzi CJ, Yan H. Promoting a new brain tumor mutation: TERT promoter mutations in CNS tumors. Acta Neuropathol. 2013 Dec;126(6):789-92. doi: 10.1007/s00401-013-1207-5. PubMed PMID: 24217890; PubMed Central PMCID: PMC3888653.
  14. Pirozzi CJ, Reitman ZJ, Yan H. Releasing the block: setting differentiation free with mutant IDH inhibitors. Cancer Cell. 2013 May 13;23(5):570-2. doi: 10.1016/j.ccr.2013.04.024. PubMed PMID: 23680144; PubMed Central PMCID: PMC4465106.
  15. Killela PJ*, Reitman ZJ*, Jiao Y*, Bettegowda C*, Agrawal N, Diaz LA Jr, Friedman AH, Friedman H, Gallia GL, Giovanella BC, Grollman AP, He TC, He Y, Hruban RH, Jallo GI, Mandahl N, Meeker AK, Mertens F, Netto GJ, Rasheed BA, Riggins GJ, Rosenquist TA, Schiffman M, Shih IeM, Theodorescu D, Torbenson MS, Velculescu VE, Wang TL, Wentzensen N, Wood LD, Zhang M, McLendon RE, Bigner DD, Kinzler KW, Vogelstein B, Papadopoulos N, Yan H. TERT promoter mutations occur frequently in gliomas and a subset of tumors derived from cells with low rates of self-renewal. Proc Natl Acad Sci U S A. 2013 Apr 9;110(15):6021-6. doi: 10.1073/pnas.1303607110. Epub 2013 Mar 25. PubMed PMID: 23530248; PubMed Central PMCID: PMC3625331.
  16. Bettegowda C, Agrawal N, Jiao Y, Wang Y, Wood LD, Rodriguez FJ, Hruban RH, Gallia GL, Binder ZA, Riggins CJ, Salmasi V, Riggins GJ, Reitman ZJ, Rasheed A, Keir S, Shinjo S, Marie S, McLendon R, Jallo G, Vogelstein B, Bigner D, Yan H, Kinzler KW, Papadopoulos N. Exomic sequencing of four rare central nervous system tumor types. Oncotarget. 2013 Apr;4(4):572-83. doi: 10.18632/oncotarget.964. PubMed PMID: 23592488; PubMed Central PMCID: PMC3720605.
  17. Jin G, Reitman ZJ, Duncan CG, Spasojevic I, Gooden DM, Rasheed BA, Yang R, Lopez GY, He Y, McLendon RE, Bigner DD, Yan H. Disruption of wild-type IDH1 suppresses D-2-hydroxyglutarate production in IDH1-mutated gliomas. Cancer Res. 2013 Jan 15;73(2):496-501. doi: 10.1158/0008-5472.CAN-12-2852. Epub 2012 Nov 30. PubMed PMID: 23204232; PubMed Central PMCID: PMC3548957.
  18. Reitman ZJ, Choi BD, Spasojevic I, Bigner DD, Sampson JH, Yan H. Enzyme redesign guided by cancer-derived IDH1 mutations. Nat Chem Biol. 2012 Nov;8(11):887-9. doi: 10.1038/nchembio.1065. Epub 2012 Sep 23. PubMed PMID: 23001033; PubMed Central PMCID: PMC3487689.
  19. Jiao Y, Killela PJ, Reitman ZJ, Rasheed AB, Heaphy CM, de Wilde RF, Rodriguez FJ, Rosemberg S, Oba-Shinjo SM, Nagahashi Marie SK, Bettegowda C, Agrawal N, Lipp E, Pirozzi C, Lopez G, He Y, Friedman H, Friedman AH, Riggins GJ, Holdhoff M, Burger P, McLendon R, Bigner DD, Vogelstein B, Meeker AK, Kinzler KW, Papadopoulos N, Diaz LA, Yan H. Frequent ATRX, CIC, FUBP1 and IDH1 mutations refine the classification of malignant gliomas. Oncotarget. 2012 Jul;3(7):709-22. doi: 10.18632/oncotarget.588. PubMed PMID: 22869205; PubMed Central PMCID: PMC3443254.
  20. Riggs KR, Reitman ZJ, Mielenz TJ, Goodman PC. Relationship Between Time of First Publication and Subsequent Publication Success Among Non-PhD Physician-Scientists. J Grad Med Educ. 2012 Jun;4(2):196-201. doi: 10.4300/JGME-D-11-00068.1. PubMed PMID: 23730441; PubMed Central PMCID: PMC3399612.
  21. Reitman ZJ, Jin G, Karoly ED, Spasojevic I, Yang J, Kinzler KW, He Y, Bigner DD, Vogelstein B, Yan H. Profiling the effects of isocitrate dehydrogenase 1 and 2 mutations on the cellular metabolome. Proc Natl Acad Sci U S A. 2011 Feb 22;108(8):3270-5. doi: 10.1073/pnas.1019393108. Epub 2011 Feb 2. PubMed PMID: 21289278; PubMed Central PMCID: PMC3044380.
  22. Jin G, Reitman ZJ, Spasojevic I, Batinic-Haberle I, Yang J, Schmidt-Kittler O, Bigner DD, Yan H. 2-hydroxyglutarate production, but not dominant negative function, is conferred by glioma-derived NADP-dependent isocitrate dehydrogenase mutations. PLoS One. 2011 Feb 4;6(2):e16812. doi: 10.1371/journal.pone.0016812. PubMed PMID: 21326614; PubMed Central PMCID: PMC3033901.
  23. Lopez GY, Reitman ZJ, Solomon D, Waldman T, Bigner DD, McLendon RE, Rosenberg SA, Samuels Y, Yan H. IDH1(R132) mutation identified in one human melanoma metastasis, but not correlated with metastases to the brain. Biochem Biophys Res Commun. 2010 Jul 30;398(3):585-7. doi: 10.1016/j.bbrc.2010.06.125. Epub 2010 Jul 13. PubMed PMID: 20603105; PubMed Central PMCID: PMC2987603.
  24. Reitman ZJ, Yan H. Isocitrate dehydrogenase 1 and 2 mutations in cancer: alterations at a crossroads of cellular metabolism. J Natl Cancer Inst. 2010 Jul 7;102(13):932-41. doi: 10.1093/jnci/djq187. Epub 2010 May 31. Review. PubMed PMID: 20513808; PubMed Central PMCID: PMC2897878.
  25. Reitman ZJ, Olby NJ, Mariani CL, Thomas R, Breen M, Bigner DD, McLendon RE, Yan H. IDH1 and IDH2 hotspot mutations are not found in canine glioma. Int J Cancer. 2010 Jul 1;127(1):245-6. doi: 10.1002/ijc.25017. PubMed PMID: 19877121; PubMed Central PMCID: PMC3498760.
  26. Reitman ZJ, Parsons DW, Yan H. IDH1 and IDH2: not your typical oncogenes. Cancer Cell. 2010 Mar 16;17(3):215-6. doi: 10.1016/j.ccr.2010.02.024. PubMed PMID: 20227034; PubMed Central PMCID: PMC4467912.
  27. Shen M, Reitman ZJ, Zhao Y, Moustafa I, Wang Q, Arnold JJ, Pathak HB, Cameron CE. Picornavirus genome replication. Identification of the surface of the poliovirus (PV) 3C dimer that interacts with PV 3Dpol during VPg uridylylation and construction of a structural model for the PV 3C2-3Dpol complex. J Biol Chem. 2008 Jan 11;283(2):875-88. doi: 10.1074/jbc.M707907200. Epub 2007 Nov 9. PubMed PMID: 17993457; PubMed Central PMCID: PMC2186065.